Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Eckert & Ziegler Strahlen- und Medizintechnik AG, DE0005659700

Eckert & Ziegler Strahlen- und Medizintechnik AG, DE0005659700

18.05.2021 - 09:17:17

Eckert & Ziegler Granted Exclusive Distribution Rights by Telix Pharmaceuticals for Prostate Cancer Diagnostic

Prostate cancer is the most common type of cancer in men in Germany, with approximately 68,000 cases in 2020, a significantly higher incidence than either lung cancer (38,000 new cases) or bowel cancer (31,000 new cases).[3] Prostate cancer was also the second most common cause of cancer death in men, with over 15,000 men dying from the disease in Germany in 2020. More than 290,000 German men were estimated to be living with prostate cancer in 2020.[1] Fendler W et al. JAMA Oncol. 2019; 5(6): 856-863.[2] Hofman M et al. The Lancet. 2020; 395: 1208-1216.[3] IARC Global Cancer Observatory, 2020.About Eckert & Ziegler. Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees, is one of the world's largest providers of isotope-related components for nuclear medicine and radiation therapy. The company offers services for radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche B?rse.Contributing to saving lives.About Telix Pharmaceuticals Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.comAbout Illuccix(R) Telix's lead investigational product, Illuccix(R) (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA). Telix is also progressing marketing authorisation applications for Illuccix(R) in the European Union and Canada. None of Telix's products have received a marketing authorisation in any jurisdiction.Eckert & Ziegler AG Contact: Karolin Riehle, Investor Relations Robert-R?ssle-Str. 10, 13125 Berlin, Germany Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

Telix Pharmaceuticals Contact: Dr. Stewart Holmstrom, Investor Relations Suite 401, 55 Flemington Road, North Melbourne, VIC 3051, Australia Email: stewart.holmstrom@telixpharma.com

18.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-R?ssle-Str.10 13125 Berlin

Germany Phone: +49 30 941084-138 Fax: +49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Indices: SDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1197562 ? End of News DGAP News Service


@ dgap.de